سعر سولبادين 24 كبسولة 2022

Solpadeine capsules, pack of 24 (Chefaro Ireland DAC); per the Irish SmPC of the same brand each capsule contains paracetamol 500 mg, codeine phosphate hemihydrate 8 mg and caffeine 30 mg, for short-term relief of acute moderate pain not relieved by paracetamol or ibuprofen alone.

• Short-term treatment of acute, moderate pain not relieved by paracetamol or ibuprofen alone (headache including migraine, toothache, backache, cold/influenza, menstrual and musculoskeletal pain)Population: Patients older than 12 yearsHealth Products Regulatory Authority (HPRA), Ireland

• Paracetamol (very rare): thrombocytopenia, agranulocytosis, anaphylaxis, hypersensitivity skin reactions including serious reactions (SJS, TEN, AGEP), bronchospasm in aspirin/NSAID-sensitive patients, hepatic dysfunction, sterile pyuria; high anion gap metabolic acidosis (frequency not known).International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Codeine: constipation, nausea, vomiting, dyspepsia, dry mouth, drowsiness, dizziness, worsening headache with prolonged use, blurred vision, palpitations, flushing, postural hypotension, pruritus, sweating, difficulty with micturition, dependence and withdrawal syndrome, and acute pancreatitis in patients with prior cholecystectomy.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Caffeine: dizziness, headache, tremor, nervousness and irritability; combined with dietary caffeine it may cause insomnia, restlessness, anxiety, gastrointestinal upset and palpitations.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity to the active substances or excipients; acute asthma or respiratory depression; chronic constipation; known CYP2D6 ultra-rapid metabolisers; breastfeeding.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• All patients 0-18 years undergoing tonsillectomy and/or adenoidectomy for obstructive sleep apnoea; children under 12 years for symptomatic treatment of cough and/or cold.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Opioid use disorder: tolerance, dependence and abuse may develop with repeated use; abuse may cause overdose and death, and hepatotoxicity has been reported with prolonged high-dose use of codeine/paracetamol. Do not use for more than 3 days without medical advice; withdrawal symptoms may occur.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• CYP2D6 metabolism: poor metabolisers may get inadequate analgesia; extensive or ultra-rapid metabolisers are at risk of opioid toxicity (confusion, somnolence, shallow breathing, miosis, nausea, constipation; rarely life-threatening respiratory depression).International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Concomitant benzodiazepines or other sedatives may cause sedation, respiratory depression, coma and death; combine only when alternatives are not possible, at the lowest dose and shortest duration.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Benzodiazepines and other sedatives / CNS depressants (alcohol, hypnotics, tricyclics, phenothiazines)Additive CNS depression: sedation, respiratory depression, coma and death; limit dose and duration.Health Products Regulatory Authority (HPRA), Ireland
• Monoamine oxidase inhibitors (MAOIs)Risk of serotonin syndrome with opiates; do not take concurrently or within 2 weeks of stopping an MAOI.Health Products Regulatory Authority (HPRA), Ireland
• Warfarin and other coumarinsProlonged regular paracetamol use may enhance the anticoagulant effect and bleeding risk; occasional doses have no significant effect.Health Products Regulatory Authority (HPRA), Ireland

• Avoid use in pregnancy unless advised by a physician, including during labour (risk of neonatal respiratory depression); regular codeine use may cause fetal dependence and neonatal withdrawal; caffeine above 200 mg/day may increase the risk of miscarriage and low birth weight.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland
• Contraindicated during breastfeeding: in CYP2D6 ultra-rapid metabolisers morphine levels in milk may cause infant opioid toxicity, which may be fatal; paracetamol and caffeine pass into milk in clinically insignificant amounts.International label, same formulation · Health Products Regulatory Authority (HPRA), Ireland

• Paracetamol: Analgesic and antipyretic (Irish SmPC section 5.1).
• Codeine phosphate hemihydrate: Centrally acting weak analgesic acting on mu-opioid receptors; its analgesic effect is due mainly to CYP2D6 conversion to morphine (Irish SmPC sections 4.4 and 5.1).
• Caffeine: Potent CNS stimulant (Irish SmPC section 5.1).